Osimertinib has been approved as a first‐line treatment [7] in most countries, including the United States and the European Union, for patients with locally advanced or metastatic NSCLC [8, 9] harboring an EGFR exon 19 deletion or exon 21 L858R mutation (activating EGFR mutations) [10]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.